Landau Jeffrey B 4

4 · CytomX Therapeutics, Inc. · Filed Feb 6, 2023

Form 4

Period: 2023-02-02

Chief Business Officer

Transactions

Award
Common Stock
2023-02-02+40,000→ 70,725 total
Award
Performance Stock Units (PSUs)
2023-02-02+75,000→ 75,000 total
→ Common Stock (75,000 underlying)
Award
Stock Option (Right to Buy)
2023-02-02+100,000→ 100,000 total
Exercise: $2.59Exp: 2033-02-01→ Common Stock (100,000 underlying)

Holdings

Footnotes (4)

[F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
[F2]Includes 56,274 RSUs.
[F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date.
[F4]Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

Documents

1 file